166 related articles for article (PubMed ID: 21540864)
21. HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX.
Tozbikian GH; Zynger DL
Breast J; 2018 Jul; 24(4):535-540. PubMed ID: 29498449
[TBL] [Abstract][Full Text] [Related]
22. Chromogenic
Ali AHM; Yahya AQ; Mohammed HL
Open Access Maced J Med Sci; 2019 Jun; 7(12):1917-1925. PubMed ID: 31406529
[TBL] [Abstract][Full Text] [Related]
23. An alternative and sensitive method based on LCM and Q-PCR for HER2 testing in breast cancer.
Fetica B; Balacescu O; Balacescu L; Rus M; Berindan-Neagoe I
Cancer Biomark; 2014; 14(2-3):129-35. PubMed ID: 24878813
[TBL] [Abstract][Full Text] [Related]
24. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.
Dabbs DJ; Klein ME; Mohsin SK; Tubbs RR; Shuai Y; Bhargava R
J Clin Oncol; 2011 Nov; 29(32):4279-85. PubMed ID: 21990395
[TBL] [Abstract][Full Text] [Related]
25. Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer.
Hillig T; Thode J; Breinholt MF; Franzmann MB; Pedersen C; Lund F; Mygind H; Sölétormos G; Rudnicki M
APMIS; 2012 Dec; 120(12):1000-7. PubMed ID: 23030524
[TBL] [Abstract][Full Text] [Related]
26. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
van de Vijver M; Bilous M; Hanna W; Hofmann M; Kristel P; Penault-Llorca F; Rüschoff J
Breast Cancer Res; 2007; 9(5):R68. PubMed ID: 17922920
[TBL] [Abstract][Full Text] [Related]
27. Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival.
Saxby AJ; Nielsen A; Scarlett CJ; Clarkson A; Morey A; Gill A; Smith RC
Am J Surg Pathol; 2005 Sep; 29(9):1125-34. PubMed ID: 16096400
[TBL] [Abstract][Full Text] [Related]
28. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
29. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
Boers JE; Meeuwissen H; Methorst N
Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
[TBL] [Abstract][Full Text] [Related]
30. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH.
Jensen SG; Thomas PE; Christensen IJ; Balslev E; Hansen A; Høgdall E
APMIS; 2020 Nov; 128(11):573-582. PubMed ID: 32860265
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of RT-PCR in assessing HER 2 gene expression versus traditional IHC and FISH in breast cancer patients.
Suryavanshi M; Mehta A; Jaipuria J; Kumar D; Vishwakarma G; Panigrahi MK; Verma H; Saifi M; Sharma S; Tandon S; Doval DC; Das BC
Breast Cancer; 2018 Jul; 25(4):416-430. PubMed ID: 29427123
[TBL] [Abstract][Full Text] [Related]
33. HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer.
Bae YK; Gong G; Kang J; Lee A; Cho EY; Lee JS; Suh KS; Lee DW; Jung WH;
J Breast Cancer; 2012 Dec; 15(4):381-7. PubMed ID: 23346165
[TBL] [Abstract][Full Text] [Related]
34. Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer.
El Hadi H; Abdellaoui-Maane I; Kottwitz D; El Amrani M; Bouchoutrouch N; Qmichou Z; Karkouri M; ElAttar H; Errihani H; Fernandez PL; Bakri Y; Sefrioui H; Moumen A
Gene; 2017 Mar; 605():114-122. PubMed ID: 28039034
[TBL] [Abstract][Full Text] [Related]
35. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.
Lee S; de Boer WB; Fermoyle S; Platten M; Kumarasinghe MP
Histopathology; 2011 Nov; 59(5):832-40. PubMed ID: 22092394
[TBL] [Abstract][Full Text] [Related]
36. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.
Lambein K; Praet M; Forsyth R; Van den Broecke R; Braems G; Matthys B; Cocquyt V; Denys H; Pauwels P; Libbrecht L
J Clin Pathol; 2011 Mar; 64(3):200-7. PubMed ID: 21177747
[TBL] [Abstract][Full Text] [Related]
37. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
[TBL] [Abstract][Full Text] [Related]
38. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
39. Detection of Gene Amplification by Multiplex Ligation-Dependent Probe Amplification in Comparison with In Situ Hybridization and Immunohistochemistry.
Tabarestani S; Ghaderian SM; Rezvani H
Asian Pac J Cancer Prev; 2015; 16(17):7997-8002. PubMed ID: 26625832
[TBL] [Abstract][Full Text] [Related]
40. Her2 amplification status in Iranian breast cancer patients: comparison of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH).
Ghaffari SR; Sabokbar T; Dastan J; Rafati M; Moossavi S
Asian Pac J Cancer Prev; 2011; 12(4):1031-4. PubMed ID: 21790246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
